Irritable Bowel Syndrome Treatment Market Foreseen To Grow Exponentially Over 2025
Global Irritable Bowel Syndrome Treatment Market by Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and others), Medical Condition (IBS-constipation and IBS-diarrhea), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies) and Region - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025
The treatment of irritable bowel syndrome majorly revolves around relieving the patient from the symptoms associated with the condition, as the causes behind occurrence of irritable bowel syndrome are yet to be established. Patients suffering from irritable bowel syndrome show symptoms such as abdominal pain, diarrhea, and constipation. Long-term and recurring presence of these symptoms signals the possibility of irritable bowel syndrome. The treatment depends on severity of these symptoms, which are distinguished as mild, moderate, and severe. Mild symptoms do not significantly affect the quality of life. The global irritable bowel syndrome treatment market was valued at US$ 726.1 million in 2016 and is expected to witness a robust CAGR of 12.9% over the forecast period (2017-2025).
The disease is often linked with dietary, lifestyle factors, and stress, which can be controlled by managing stress levels, diet, and exercise. Severe symptoms need to be treated through medication prescribed by physicians. Two major therapy options are available for the treatment of IBS, namely, medical or drug therapy and nutritional therapy. Medical therapy includes drugs for relieving the